Werewolf Therapeutics Inc
Werewolf Therapeutics Inc (HOWL) Options Open Interest
HOWL options open interest is 6,026 contracts. The 2-week average daily volume is 296 contracts across the chain.
Read more
Monitoring HOWL open interest helps you see where real money is positioned on Werewolf Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Werewolf Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor HOWL options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising HOWL options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Werewolf Therapeutics Inc to settle.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma.
The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where HOWL open interest is concentrated. Our scanner maps Werewolf Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Werewolf Therapeutics Inc's options open interest as the signal it is, not as an afterthought.
| 2.50 | — | 0.05 | 0.05 | 297% | +0.1760 | 3,500 |
| 1.00 | — | 0.20 | 0.20 | 220% | +0.5927 | 130 |
| 5.00 | — | 0.40 | 0.40 | 834% | +0.5845 | 99 |
| 7.50 | — | 0.05 | 0.05 | 488% | +0.1316 | 87 |
| 0.50 | 0.50 | 0.75 | 0.63 | 508% | +0.8779 | 4 |
| 2.50 | 1.25 | 1.80 | 1.53 | 212% | -0.9397 | 21 |
| 5.00 | 3.70 | 4.30 | 4.00 | 87% | -1.0000 | 3 |
| 1.00 | — | 0.45 | 0.45 | 487% | -0.2820 | 1 |
| 0.50 | — | 0.30 | 0.30 | 866% | -0.0848 | 0 |
| 1.50 | 0.25 | 0.80 | 0.53 | 112% | -0.9213 | 0 |
As of September 24, 2026
Follow the money
Track HOWL open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→